Change search
ReferencesLink to record
Permanent link

Direct link
Comparison of the mucosal adjuvant Endocine™ with two well-known adjuvants: cholera toxin and alum
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Health Sciences.
Advanced Medical Research Laboratory, Mitsubishi Tanabe Pharma Corporation, Japan.
Advanced Medical Research Laboratory, Mitsubishi Tanabe Pharma Corporation, Japan.
Advanced Medical Research Laboratory, Mitsubishi Tanabe Pharma Corporation, Japan.
Show others and affiliations
2015 (English)In: Jacobs Journal of Vaccine and Vaccination, Vol. 1, no 1, 006Article in journal (Refereed) Published
Abstract [en]

To enable efficient mucosal vaccination with split or subunit antigens, an adjuvant is often needed. To date, no mucosal adjuvants are approved for human use, however, there are a variety of mucosal adjuvants in development, including the liposome-based adjuvant Endocine™. The aim of this study was to evaluate split influenza antigens together with Endocine™ and in order to assess the potency of Endocine™, the induction of humoral immune responses were compared to those following influenza vaccination with cholera toxin (CT) or aluminum salt (alum). We show that Endocine™ significantly enhances influenza-specific immune responses in intranasally immunized mice compared to nonadjuvanted vaccine. Furthermore, vaccines adjuvanted with Endocine™ evoked comparable serum IgG and virus neutralizing (VN) antibody titers as nasal vaccines adjuvanted with CT. Compared to parenteral vaccination with alum, Endocine™ triggered significantly higher mucosal and serum IgA titers, and similar VN titers. Taken together, these results support further development of Endocine™ as a mucosal adjuvant and as part of a nasal influenza vaccine candidate.

Place, publisher, year, edition, pages
Jacobs Publishers , 2015. Vol. 1, no 1, 006
Keyword [en]
Mucosal adjuvant; nasal immunization; vaccine; Endocine; influenza; neutralizing antibodies
National Category
Clinical Laboratory Medicine Cell and Molecular Biology
URN: urn:nbn:se:liu:diva-117979OAI: diva2:812606
Available from: 2015-05-19 Created: 2015-05-19 Last updated: 2015-09-09Bibliographically approved
In thesis
1. Nasal vaccination using novel mucosal adjuvants: with main focus on influenza A virus
Open this publication in new window or tab >>Nasal vaccination using novel mucosal adjuvants: with main focus on influenza A virus
2015 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Influenza viruses have sporadically caused pandemics during the last century, with the most severe occurring in 1918 when the “Spanish flu”, an A/H1N1 influenza virus, passed around the globe killing about 20-100 million people. Today 250 000-500 000 deaths occur annually due to influenza virus or secondary infection after influenza, e.g. pneumonia. Influenza viruses cause severe infections in susceptible age groups like children and elderly and in individuals with impaired immune response due to other medical conditions. The best way to prevent an influenza epidemic is by vaccination. Since the 1950´s we have vaccines against seasonal flu, but vaccine efficacy is not 100 % and there is a need to develop better and more effective vaccines, especially for the risk groups. Since the virus enters the host through the nasal cavity, nasal vaccination is a good approach. By stimulating a mucosal immune response already in the nasal cavity, the goal with nasal vaccination is to stop the virus before it enters the host. Nasal vaccination also reduces the risk of transmission of blood-borne diseases, and is less painful and easier to administer, compared to injectable vaccines.

In order to be able to use less immunogenic antigens, like split and subunit antigens, as nasal vaccine components, an adjuvant is needed to enhance the immune response. At the moment there is no licensed mucosal adjuvant for human use. Several studies are ongoing, but it is a complicated and long way to reach the market. In this thesis nasal vaccination with influenza antigen together with the mucosal adjuvant Endocine™ and other mucosal adjuvants has been evaluated. The Endocine™ adjuvant has been shown to be safe and well tolerated in clinical trials. Depending on the pathogen of interest, different approaches are necessary. For HIV, DNA-vaccination has been evaluated together with a plasmid encoding Salmonella typhimurium flagellin C and the mucosal adjuvant N3. The results found in paper I-IV show that by adding adjuvant to the antigen enhances the protective immune response towards the antigen. Enhanced systemic, mucosal and cell-mediated immunity were observed. Hopefully in the future these adjuvants evaluated in this thesis, will be used in vaccines for humans.

Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2015. 57 p.
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1460
National Category
Biochemistry and Molecular Biology Immunology in the medical area
urn:nbn:se:liu:diva-117981 (URN)10.3384/diss.diva-117981 (DOI)978-91-7519-060-0 (print) (ISBN)
Public defence
2015-05-28, Eken, Campus US, Linköping, 09:00 (Swedish)
Available from: 2015-05-19 Created: 2015-05-19 Last updated: 2015-05-19Bibliographically approved

Open Access in DiVA

fulltext(1114 kB)74 downloads
File information
File name FULLTEXT01.pdfFile size 1114 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Link to full text

Search in DiVA

By author/editor
Falkeborn, TinaHinkula, Jorma
By organisation
Division of Microbiology and Molecular MedicineFaculty of Health Sciences
Clinical Laboratory MedicineCell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 74 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 259 hits
ReferencesLink to record
Permanent link

Direct link